1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Phosphomannose isomerase deficiency, mannosephosphate isomerase deficiency, MPI-CDG, CDG-Ib, Saguenay-Lac Saint-Jean syndrome, protein-losing enteropathy-hepatic fibrosis syndrome.
1.2 OMIM# of the disease 602579.
1.3 Name of the analysed genes or DNA/chromosome segments MPI.
OMIM# of the gene(s)
154550.
Mutational spectrum
Eighteen mutations have been reported, including 15 missense mutations, 2 frame-shift-causing mutations and 1 splicing defect; 1 (http://www.lovd.nl/MPI). One frame-shift mutation was caused by an insertion resulting in an unstable transcript that was hardly detectable at the mRNA level. This emphasizes the importance of mutation analysis at the genomic DNA level. 2 The standard reference sequence indicating reported variants (ENSG00000178802) and a reference for exon numbering (ENST00000352410) can be found at http://www.ensembl.org.
Analytical methods
Sanger sequencing of the eight exons and flanking intronic sequences of the MPI gene (NCBI reference sequence: NM_002435.1).
Analytical validation
Sanger sequencing identifies mutations in 499% of patients with an enzymatically confirmed MPI deficiency. Deep intronic mutations, large deletions and duplications would not be detected using this approach.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence. If known to be variable between ethnic groups, please report) Some 25 patients have been reported ('Asian' , Austrian, Bulgarian, Canadian, Danish, Dutch, French, German, Italian, Lebanese, Polish, Spanish and Turkish). The frequency and the prevalence of the disease are not known.
Diagnostic setting
MPI-CDG is an autosomal recessive disorder with a hepaticintestinal presentation (review in de Lonlay and Seta 3 ). Digestive symptoms are vomiting, intractable diarrhoea and malnutrition, while hepatic disease is characterized by hepatomegaly and liver fibrosis. In addition, there is frequent thrombosis and hyperinsulinism. Untreated patients manifesting the disease before one year of age died in the first years of life. 4, 5 Intrafamilial heterogeneity was shown in two siblings: one died at 5 years with hepatic fibrosis while the other survived into adulthood without treatment. 6 The biochemical screening test 'par excellence' is serum transferrin isoelectrofocusing. The next diagnostic step is enzymatic analysis of phosphomannose isomerase activity in leucocytes or fibroblasts. The diagnosis has to be confirmed by mutation analysis of MPI. This will permit heterozygote detection in the family and prenatal diagnosis. 
TEST CHARACTERISTICS
Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Close to 100% when using the serum transferrin isoelectrofocusing test. 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Close to 100%.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
100%, based on positive transferrin isoelectrofocusing screening and MPI mutation analysis.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100%. Index case in that family had not been tested: 100%. 
CLINICAL UTILITY

How is the cost effectiveness of alternative diagnostic methods to be judged?
The enzymatic test is only available in a limited number of laboratories (see orpha.net for the list).
Will disease management be influenced by the result of a genetic test?
No &
Yes 2
Therapy (please describe)
At present, MPI-CDG is the only CDG for which an efficient treatment is available, namely, oral mannose. Mannose enters the cell via a specific transporter and is converted to mannose 6-phosphate, thus circumventing the metabolic bloc. 9 The recommended dosis is 0.2 g/kg four times a day. Prognosis (please describe)
Patients with a severe clinical presentation die without mannose therapy. This treatment stops vomiting and hypoglycaemia after a few weeks. Diarrhoea and biological parameters normalize within a year. Hepatomegaly persists in some cases. Rarely patients reach symptomless adulthood without mannose treatment. 6 Management (please describe) See therapy.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.9 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe):
In affected persons mannose should be started immediately after the diagnosis in order to prevent liver cirrhosis and liver insufficiency.
If the test result is negative (please describe):
No further follow-up is required in subjects from families with a known genetic defect. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
Not applicable as an efficient treatment is available.
